Named patient programs (NPPs) enable physicians and patients in Europe to access medications that have been approved by the European Medicines Agency (EMEA), but not yet launched commercially in European Union (EU) member countries. Regulations also allow patients to access drugs that are approved outside of the EU, but not yet in their home countries. In both scenarios, requests for access are made by physicians on behalf of individuals, or named patients.
Ceplene is available on a named patient basis in Europe and in dozens of other key…
Time Frame for Planning a Named Patient Program
Named Patient Program Requirements in Select EU Member States